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Regulatory delays in a multinational
clinical stroke trial
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Iwona Kurkowska-Jastrzebska7, Malcolm R Macleod2,
George Ntaios8, G€otz Thomalla9, Philip M Bath10 and
H Bart van der Worp1
Abstract
Introduction: The initiation and conduct of randomised clinical trials are complicated by multiple barriers, including
delays in obtaining regulatory approvals. Quantitative data on the extent of the delays due to national or local review in
randomised clinical trials is scarce.
Materials and methods: We assessed the times needed to obtain regulatory approval and to initiate a trial site for an
academic, EU-funded, phase III, randomised clinical trial of pharmacological prevention of complications in patients with
acute stroke in over 80 sites in nine European countries. The primary outcome was the time from the first submission to
a regulatory authority to initiation of a trial site. Secondary outcomes included time needed to complete each individual
preparatory requirement and the number of patients recruited by each site in the first 6 and 12months.
Results: The median time from the first submission to a regulatory authority to initiation of a trial site was 784 days
(IQR: 586–1102). The single most time-consuming step was the conclusion of a clinical trial agreement between the
national coordinator and the trial site, which took a median of 194 days (IQR: 93–293). A longer time to site initiation
was associated with a lower patient recruitment rate in the first six months after initiation (B¼ –0.002; p¼ 0.02).
Discussion:
Conclusion: In this EU-funded clinical trial, approximately 26months were needed to initiate a trial site for patient
recruitment. The conclusion of a contract with a trial site was the most time-consuming activity. To simplify and speed
up the process, we suggest that the level of detail of contracts for academic trials should be proportional to the risks and
commercial interests of these trials.
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Randomised clinical trials (RCTs) and meta-analyses
thereof are generally considered the best instruments
to assess whether a specific diagnostic test or treatment
is of benefit to patients or healthy persons,1 but their
initiation and conduct are hampered by multiple bar-
riers. Editorials and narrative reviews have reported
lack of funding, increasing complexity of regulations,
excessive monitoring, overinterpretation of privacy
laws, and complex and overly bureaucratic trial proce-
dures, often out of proportion to the conceivable risk
to research participants, as important obstacles.2–5 In
addition, delays in obtaining ethical, regulatory, and
legal approvals have been identified as major delaying
factors in initiating clinical trials sites.2 As a result of
these and other barriers, it has been estimated that
approximately half of the clinical trials fail to reach
their target sample size within the planned timeline.6
Quantitative evidence on the true extent of the
delays in RCTs due to institutional or legal review is
scarce and limited to a specific part of the approval
process, to specific countries and time periods.5,7,8
New regulations, such as the General Data Protection
Regulation in the European Union, have been intro-
duced in recent years, which could have major conse-
quences for institutional review and contractual
governance.
In the present study, we aimed to quantify delays
caused by legal or institutional review in the
PRECIOUS trial (PREvention of Complications to
Improve OUtcome in elderly patients with acute
Stroke). This is a multicentre, multinational clinical
trial, performed in over 80 sites in 9 European coun-
tries, and supported by the European Union’s Horizon
2020 programme.9 We provide a systematic overview of
the time period required for each regulatory approval
procedure needed to open an individual trial site and
analyse its relationship with patient recruitment.
Methods
PRECIOUS is an international, multi-centre, 3*2-fac-
torial, randomised, controlled, open-label clinical trial
with blinded outcome assessment (PROBE) of the pre-
ventive use of metoclopramide, ceftriaxone, paraceta-
mol, or any combination of these, for four days in
elderly patients with acute ischaemic stroke or intrace-
rebral haemorrhage. The trial was initiated in 2015 and
aims to recruit 3800 patients in about 80 hospitals
(both academic and general) in 9 European countries:
Estonia, Germany, Greece, Hungary, Italy, the
Netherlands, Norway, Poland, and the UK. An over-
view of the regulatory requirements for starting the
trial on international, national, regional and local
levels is provided in Table 1 and described in more
detail below.
Overview of preparatory requirements
On an international level, we requested a ‘Voluntary
Harmonisation Procedure’ (VHP) for six countries
(Estonia, Germany, Greece, Hungary, Italy and the
United Kingdom). The VHP provides a coordinated
assessment of a clinical trial application in multiple
European countries.10 Three countries were not includ-
ed in the VHP (Netherlands, Norway and Poland).
After VHP approval, subsequent evaluation on a
national level was needed by the National Competent
Authority (NCA) and leading or national Ethics
Committee (EC) in each country. The leading EC was
usually the EC affiliated to the hospital of the National
Coordinator (NC), who is the coordinating investiga-
tor for each country. In some countries (Greece, Italy),
an independent review by an Ethics Committee on a
regional (REC) or hospital (HEC) level was also
required, as well as approval from each participating
site (usually given by the Board of Directors) was
needed to endorse the practicability of conducting the
trial at that site in some countries (Table 1).
In addition and often in parallel, two types of
required legal documents were completed: a Country
Coordinator Agreement (CCA) and a Clinical Trial
Agreement (CTA). A CCA is a contract signed between
the trial sponsor, University Medical Center Utrecht
(UMCU) in the Netherlands, and the institution of
the NC of each participating country, which delegated
the responsibility for arranging legal agreements for
that country from the sponsor to the NC, in order to
prevent potential problems due to different national
laws between the participating and the Sponsor’s coun-
try. Subsequently, the institution of the NC contracted
each participating trial site in that country by means of
a CTA.
After obtaining all necessary regulatory approvals
and completing all contracts, the Site Initiation Visit
(SIV) was planned. During this meeting with the local
PRECIOUS team, a national trial monitor assessed
whether all mandatory preparations had been complet-
ed and whether the Investigator Site File contained a
copy of all the necessary documents (e.g. approval let-
ters of the regulatory authorities, lists of signatures and
CVs of trained site PRECIOUS personnel). After
approval of the SIV report by the central monitoring
team of European Clinical Research Infrastructure
Network, a site was considered ready to start recruiting
patients.
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Included sites and data collection
We included a trial site in this analysis if the start and
end dates (‘milestone dates’) for one or more of the
individual regulatory preparatory processes were avail-
able: VHP, EC, NCA, REC/HEC, local hospital
approval, CCA or CTA. A trial site was excluded if
there were specific circumstances that resulted in excep-
tional delay in opening the site (e.g. long-term sick
leave of the principal investigator that delayed all reg-
ulatory approvals). Two authors (JCdJ, HR) retrospec-
tively retrieved milestone dates from correspondence
with regulatory authorities (e.g. approval letters) and
signed contracts stored in the Trial Master File during
the trial. The start of contract negotiations was
retrieved from email correspondence and supplemented
by information from the relevant national research
teams. For each site we collected the number of includ-
ed patients in the first 6 and 12months after the date of
the SIV from the study’s electronic case file.
Measures and outcomes
We distinguished trial sites that were included in the
original submissions to the national authorities (‘orig-
inal sites’) and trial sites that expressed interest in join-
ing during the course of the trial, which had to be
added by means of an amendment because national
approvals were already obtained (‘additional sites’).
The primary outcome was the time needed to initiate
the original trial sites (‘time to site initiation’), which was
defined as the time period between the date of VHP
submission and SIV approval (for VHP countries),
between submission to the EC and SIV approval (for
the Netherlands) or between sending the CCA template
to the NC and SIV approval (for Norway and Poland,
where this was the first preparatory activity).
Secondary outcomes included (1) time to site initia-
tion for additional sites; (2) time needed to complete
each individual preparatory requirement; (3) average
time to site initiation in each of the 9 participating coun-
tries; (4) average time to site initiation in academic and
non-academic hospitals; and (5) number of patients
recruited by each site in the first 6 and 12months after
SIV. Time to site initiation for additional sites was
defined as the time between the date of the first prepa-
ratory activity (either applying for an amendment to the
EC or sending the CTA template to the hospital) and
the SIV date (defined as the last signature on the SIV
report), which means that the time needed to obtain
primary (inter)national approvals (VHP, EC, NCA,
CCA) was not included in this outcome. The time
needed for individual regulatory approvals (VHP, EC,
NCA, REC/HEC, local hospital approval) was defined
as the time period between submission date to the reg-
ulatory authority and their approval. The time needed
for concluding a contract (CCA, CTA) was defined as
the time period between the date the first draft version of
the contract was sent to the trial site (i.e. national coor-
dinator or institution lawyer), and the date of the last
signature on the contract. As some regulatory processes
may be done in parallel or may overlap, the time to site
initiation is not necessarily the sum of the time periods
needed for all individual preparatory requirements.
Statistical analysis
The time to site initiation and the time period needed
for each regulatory requirement to be completed are
Table 1. Overview of regulatory requirements for each country.
Country
International National Regional/local
VHP ECa NCA CCA CTA HEC/REC Hospitalb SIV
Estonia      –  
Germany      c – 
Greece        
Hungary      c – 
Italy        
Norway –     – – 
The Netherlands –     –  
Poland –     c – 
United Kingdom      d  
VHP: voluntary harmonisation procedure; CCA: Country Coordinator Agreement; EC: national ethics committee; NCA: National Competent
Authority; CTA: clinical trial agreement; REC: regional ethics committee; HEC: hospital ethics committee; SIV: site initiation visit.
aThe EC is the national ethics committee of a country or the leading ethics committee affiliated the hospital of the national coordinator.
bHospital stands for local hospital approval.
cNo separate submission is required, the EC or NCA contacts the REC for approval during the approval process.
dReview by the UK’s NHS Research Scotland (NRS) and Health Research Authority (HRA) were categorised under REC.
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reported in median days with interquartile range.
Differences in time to site initiation between original
and additional sites, and between academic and non-
academic hospitals were analysed with the Mann–
Whitney U test. Differences between countries were
assessed with one-way non-parametric ANOVA
(Kruskal–Wallis test). The association between
median time to initiation and patient recruitment in
the first 6 and 12months was assessed with linear
regression. The criterion for statistical significance
was set at a¼ 0.05. The data that support the findings
of this study are available from the corresponding
author upon reasonable request.
Results
During the course of PRECIOUS, 88 trial sites planned
to participate in the trial. In the present study, three
trial sites were excluded because all of the regulatory
approvals of these sites were delayed because of
extraordinary circumstances. Therefore, 85 trial sites
were included in the analysis (Figure 1). The start
date of PRECIOUS was submission to the Sponsor’s
EC on 16 October 2015.
The median time to initiation was available for 80
sites; 59 of 60 (98%) original sites (one UK site exclud-
ed because of delay of the SIV due to long absence of
the PI) and 21 of 25 (84%) additional sites. Two addi-
tional sites were excluded (both in Italy), because the
start date of the preparation period was not available,
and two sites (one in Germany, one in UK) were
excluded because the SIV was postponed for other rea-
sons (Figure 1). The median time to site initiation was
784 days (IQR: 586–1102) for the 59 original trial sites
and 234 days (IQR: 166–315; p< 0.0001) for the 21
additional trial sites. For original and additional trial
sites combined, the median time to initiation was
698 days (IQR: 409–979; Table 2).
The time needed for each separate regulatory
requirement to be completed is shown in Tables 3
and 4. The median EC and NCA review time was 87
(IQR: 37–128) and 91 (IQR: 16–132) days, respectively.
For VHP countries, the review by the NCA lasted 105
(IQR: 10–156) days. The signing process of the CCA
and CTA were the most time-consuming regulatory
requirements (Figure 2). The median time needed to
sign a CCA was 201 days (IQR: 104–492) and to sign
a CTA was 194 days (IQR: 93–293). On average, 35.9%
of the time to initiation was used for signing the CTA.
The median time to initiation was similar for aca-
demic (n¼ 24) and general (n¼ 56) hospitals (659 vs
703 days, p¼ 0.77). The median time to initiation dif-
fered significantly between countries (p < 0.0001), with
the shortest time to initiation for the Netherlands
(where approval was requested first) and the longest
for Hungary (see Table 2). A longer time to initiation
was associated with a slower patient recruitment in the
first six months after initiation (B¼ –0.002; p¼ 0.02),
but not in the first 12months (B¼ –0.003; p¼ 0.12; see
Supplementary Tables 1 and 2).
Discussion
In PRECIOUS, the median time to initiation of a pre-
planned trial site was just over two years. Negotiations
on contracts between a national coordinator and trial
sites were an important delaying factor, responsible for
approximately one third of the time needed to initiate a
trial site.
88 trial sites initiated in 
PRECIOUS
71 sites for analysis of time 
needed for contract 
completion
85 trial sites included
5 sites missing time to initiation data:
• 2 start of preparation not available 
• 2 SIV postponed (for external reasons)
• 1 long-term absence of PI
3 sites excluded with exceptional 
delay of all regulatory approvals
14 sites missing contract data:
• 1 no CTA needed 
(sponsor site)
• 13 start date of CTA 
preparations not available
80 sites for analysis of time needed to site initiation
• 24 academic vs 56 general sites
• 59 original vs 21 additional sites 
Figure 1. Flowchart of included trial sites in the current study.
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Table 2. Time to site initiation per country.
Original sites Additional sites
Country Number of sites Median (IQR) Range Number of sites Median (IQR) Range
Netherlands 10/10 504 (437–551) 238–700 4/4 175 (166–325) 166–372
Estonia 4/4 591 (573–670) 569–695 – – –
Norway 4/4 735 (574–971) 545–1025 – – –
United Kingdom 6/7 760 (718–903) 716–987 12/13 212 (163–256) 91–566
Germany 6/6 767 (605–925) 567–1096 1/2 406 –
Greece 3/3 793 (774–821) 774–821 2/2 308 287–329
Italy 9/9 813 (702–1115) 543–1131 0/2 – –
Poland 6/6 956 (812–1108) 711–1113 1/1 116 –
Hungary 13/13 1235 (1201–1285) 564–1430 1/1 1324 –
Total 59/60 784 (586–1102) 238–1430 21/25 234 (166–315) 91–1324
Notes: Time is displayed as days. Countries sorted on duration of time to initiation.
IQR: interquartile range.
Table 3. Time needed for each (inter)national regulatory approval.
Country VHP EC NCA CCA
Estonia 84 44 111 376
Germany 84 149 14 74
Greece 84 57 99 52
Hungary 84 87 153 768
Italy 84 28 163 193
Netherlands – 110 21 –
Norway – 136 91 192
Poland – 29 88 531
United Kingdom 84 119 8 209
Median (IQR) – 87 (37–128) 91 (16–132) 201 (104–492)
Notes: Time is displayed in days. The approval time is the time of the first approval (amendments for adding sites are not included).
EC: ethics committee; NCA: National Competent Authority; CCA: Country Coordinator Agreement; IQR: interquartile range; VHP: voluntary
harmonisation procedure.
Table 4. Time needed for each local regulatory approval.
CTA Local hospital approval REC
Country Number of sites Median (IQR) Number of sites Median (IQR) Number of sites Median (IQR)
Estonia 4/4 105 (52–130) 3/4 13 (5–66) – –
Germany 8/8 542 (231–779) – – – –
Greece 5/5 208 (198–281) 4/5 69 (65–82) 5/5 41 (23–61)
Hungary 13/13 328 (277–368) – – – –
Italy 1/11 51 4/11 39 (6–152) 10/11 51 (24–67)
Netherlands 13/14a 140 (60–179) 13/14a 25 (10–57) – –
Norway 1/4 81 – – – –
Poland 6/6 205 (157–252) – – – –
United Kingdom 20/20 118 (70–196) 20/20 85 (39–108) 20/20 39 (4–131)
Total 71/85 194 (93–293) 44/54 61 (22–88) 35/36 41 (14–69)
Note: Time is displayed in days.
IQR: interquartile range; CTA: Clinical Trial Agreement; REC: regional ethics committee.
aSince the UMCU was the coordinator centre, no CTA or local hospital approval had to be obtained.
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PRECIOUS is an investigator-initiated, pragmatic
clinical trial testing widely available off-patent medica-
tions that have been on the market for several decades
and that have proven to be safe in stroke patients.11,12
As a consequence, the trial was considered as low risk
by regulatory authorities. The study Sponsor had
almost full-time availability of a chief investigator,
trial coordinator, and research nurse to support the
submissions and applications. The trial was coordinat-
ed in the participating countries by experienced NCs
and research teams. In three countries (Greece,
Hungary, and Poland), a clinical research organisation
(CRO) was contracted during the course of the trial to
speed up the approval process. Nevertheless, we expe-
rienced considerable delays in obtaining ethics and hos-
pital management approvals. Considering that the
duration of the trial granted by the European Union
was 60months, more than half of the time intended to
recruit patients was spent on obtaining regulatory
approvals. In addition, we found that longer time to
site initiation was negatively associated with the
number of included patients in the first six months,
possibly because of understandable loss of momentum
and enthusiasm among some of the investigators.
Delays in obtaining regulatory approval and legal
review may therefore be an important reason why
about half of the clinical trials fail to reach their
target sample size within the planned timeline.6
Only a few previous studies evaluated delay due to
regulatory review in RCTs.5 Also, most of these studies
only looked at ethics13,14 or local hospital approval,8
instead of the entire time to initiation including con-
tract negotiations. In the British phase IV trial
SANADII on treatment of epilepsy the median ‘open-
ing time’ for study sites in 2012 and 2013 was
10.5months, but this was after ethics approval had
already been obtained.7 The study identified several
delaying factors, such as negotiating excess treatment
costs, finalising logistics, collecting CVs, and ongoing
discussions about participation. The median time of
10.5months is much shorter than the median time to
initiation of almost 25months for pre-planned trial
sites in the UK, but the starting point of VHP submis-
sion in the present study is much earlier. In addition,
SANADII was a phase IV trial whereas PRECIOUS is
phase III, and SANADII was performed only in the
UK, whereas PRECIOUS involves nine European
countries.
Obviously, we have to declare a mea culpa.
Although the study Sponsor and most of the centres
of the NCs have ample experience with clinical trials,
and all of these are partners in the PRECIOUS project
and therefore share responsibilities, they may occasion-
ally have contributed to some delays, for example
because of other obligations or priorities. This also
applies to local Principal Investigators. Most investiga-
tors work on the trial in addition to their everyday
clinical work. The trial had no commercial interest
and local investigators only receive a small reimburse-
ment for expenses for including a patient in the trial,
which could have an impact on the speed of setting up
the trial. With the exception of Greece, Hungary, and
Poland, the approval process was not supported by a
commercial CRO, which could have accelerated the
process but at considerable cost. It would be interesting
to compare our findings with those in other academic
trial with or without the involvement of a CRO, and
with those in industry-driven trials. Such a comparison
could support the development of best practice exam-
ples that could aid future clinical trials.
The current study also has other limitations. First,
the time needed for preparation of the submissions to
the regulatory authorities is not incorporated in the
duration of the approval processes. The submission
package consists of multiple forms and other docu-
ments, some of which need translation to the national
language in some countries. Therefore, the actual time
needed for ethics or hospital management approval is
longer than reported here. Secondly, we assessed the
approval process in just nine countries in Europe.
These were however relatively well distributed across
Europe.
We observed considerable overlap between the
assessments of different regulatory authorities.
Whereas the VHP is intended to facilitate and shorten
NCA approval and VHP timelines dictate that NCA
approval should follow within 10 days after VHP
approval,10 we experienced a median time for NCA
review of 105 days in the six countries that participated
in the VHP (in addition to the 84 days needed for VHP
approval). Therefore, in our experience the VHP was











VHP EC NCA CTA CCA
Figure 2. Median time per regulatory requirement.
Approval duration of national regulatory requirements sorted
based on duration. Time displayed in median number of days with
interquartile ranges.
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separate submission with often little additional value
with regard to subsequent approvals. We believe that
stricter adherence to VHP timelines should be pursued.
Likewise, the EC provides ethical approval for a clini-
cal trial and ensures that a trial is performed according
to (inter)national law and regulations. This approval
should serve as a proof of warranty for local trial
sites to conduct a clinical trial. However, in our expe-
rience, institutions at regional or hospital level may
repeat a large part of the same approval procedure as
the EC. In our opinion, countries should strive for a
single regulatory review process that serves as global
approval in that country. Any local review afterwards
should be limited to issues related to local practicability
and should be bound to specific timeframes. In addi-
tion, we support proposals to make regulatory require-
ments proportional to the risk of the study. This is
likely to shorten the approval process and to increase
patient recruitment.
Moreover, clinical trials could benefit from a univer-
sally accepted template for national contracts. In
PRECIOUS, we used a local template for the CCAs.
The CCA was reviewed by lawyers in each country,
who were often not familiar with this format. In addi-
tion, there are no established timeframes for legal
review of research contracts (both CCA and CTA).
Legal departments of hospitals or institutions often
have a high work load with limited capacity and the
quick opening of a trial site may not be their top pri-
ority. This regularly resulted in recurrent discussions
between lawyers of both parties, often on details of
which the relevance was not immediately clear to the
investigators, interrupted by lengthy periods of appar-
ent inactivity. This is illustrated by a delay of 201 days
for the CCA and 194 days for the CTA. Moreover,
most of the times the CCA and CTA were handled
consecutively. We suggest that an international tem-
plate for clinical trials should be developed, with spe-
cific timeframes and deadlines for local lawyers to
complete legal review.
In conclusion, ethical and legal review including the
evaluation of contracts with study sites lead to serious
delays in initiating trial sites, which reduce time avail-
able for patient recruitment, and results in substantial
increases in efforts and costs, jeopardising the conduct
of academic clinical trials.
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